Revolution Medicines, Inc. (RVMD)
Revolution Medicines is a clinical-stage biotechnology company developing targeted medicines for cancer and relies on third-party suppliers, some of which are sole sources of drug supplies.
| Ticker | RVMD |
|---|
| Company | Revolution Medicines, Inc. |
|---|
| Exchange | Nasdaq |
|---|
| Headquarters | REDWOOD CITY, CA |
|---|
Income statement — period ending 2026-06-30
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$649,699,000 |
|---|
| Earnings Per Share, Basic | -3 USD/shares |
|---|
| Earnings Per Share, Diluted | -3 USD/shares |
|---|
| Goodwill, Impairment Loss | $0 |
|---|
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | -$644,371,000 |
|---|
| InterestExpenseNonoperating | $23,781,000 |
|---|
| Investment Income, Interest | $35,579,000 |
|---|
| Net Income (Loss) Attributable to Parent | -$644,371,000 |
|---|
| Net Income (Loss) Available to Common Stockholders, Basic | -$644,371,000 |
|---|
| Nonoperating Income (Expense) | -$139,239,000 |
|---|
| Operating Expenses | $505,132,000 |
|---|
| Operating Income (Loss) | -$505,132,000 |
|---|
| Other Nonoperating Income (Expense) | -$6,000 |
|---|
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | -$1,098,187,000 |
|---|
| Research and Development Expense | $394,919,000 |
|---|
| Share-based Payment Arrangement, Noncash Expense | $154,299,000 |
|---|
| Weighted Average Number of Shares Outstanding, Diluted | 210,893,604 shares |
|---|
| Weighted Average Number of Shares Outstanding, Basic | 210,893,604 shares |
|---|
Sourced from SEC EDGAR/XBRL filings via StockSpectro.
View full interactive research on StockSpectro